As a breast medical oncologist, my mission and goal have always been to mitigate breast cancer. After 20 years in academia and clinical practice, my current role as the Global Head of Breast Cancer and Breast Cancer Research Strategy allows me to pioneer and expand novel translational global research and innovative clinical trial development that accelerate the approval of established and novel drugs in the key areas of excellence at AstraZeneca, tumour resistance/ targeted therapies, DNA damage response, antibody-drug conjugates, and immuno-oncology.

My overarching vision is to promote paradigm-shifting and practice-changing treatments in breast cancer to decrease mortality, morbidity, and health disparities, as well as address the critical knowledge gaps in the breast cancer medical field. 

Before joining AstraZeneca, I was a Professor of Medicine and Ingram Professor of Cancer Research at Vanderbilt University Medical Center for 18 years, with a successful track record of mentoring fellows and junior faculty throughout my career. As a breast cancer medical oncologist, I have provided cutting-edge care to thousands of patients. I have extensive experience with novel therapeutics in phase I, II and III clinical trials, having been the principal investigator on more than 90 clinical trials spanning from phase I to phase III. My translational research in breast cancer focused on identifying targetable pathways and mechanisms of treatment resistance, which have been recognized and funded by the NCI (K23 and SPORE in Breast Cancer), SU2C/ AACR, Susan G. Komen Foundation and the Breast Cancer Research Foundation, and published in more than 135 peer-reviewed journals. I have chaired, co-chaired or been a member of many national and international health services cancer leadership committees in the US, such as ECOG-ACRIN Breast Core Committee, National Comprehensive Cancer Network (NCCN) Breast Cancer Panel of Experts, Translational Breast Cancer Research Consortium (TBCRC) amongst many others.

Bench-to-bed research has led us to alter the breast cancer treatment paradigm and practice, making treatments more effective and patient-centred. I am excited about the research we are pursuing that will help decrease mortality, morbidity and health disparities for breast cancer patients

Ingrid A. Mayer Global Clinical Head for Breast Cancer and Breast Cancer Strategy

Honor

Komen Scholar (2018-2022)


Shortlisted

Top Doctors; Castle Connolly (2013-2021)


Award

VICC Star Award for Leadership in Cancer Clinical Investigation (2011-2021)



Headshot of Ingrid Mayer, Global Clinical Head Breast Cancer and Breast Cancer Strategy, Research & Development, at AstraZeneca.

CURRENT ROLE

Professor of Medicine and Ingram Professor of Cancer Research at Vanderbilt University Medical Center / Global Head of Breast Cancer and Breast Cancer Research Strategy

2021

Oncology Section Chief, Division of Hematology/ Oncology, Vanderbilt University Medical Center

2021

Membership Committee Member; European Society of Medical Oncology

2014 – 2021

Clinical Leader of the Breast Cancer Program and Clinical Leader of the NCI Breast Cancer Specialized Program of Research Excellent (SPORE), Vanderbilt-Ingram Cancer Center

 Featured publications

Phase Ib Dose Escalation Trial of RO4929097 (a γ-secretase inhibitor) in Combination with Exemestane in Patients with ER + Metastatic Breast Cancer (MBC)

Means-Powell JA, Mayer IA, Ismail-Khan R, Del Valle L, Tonetti D, Abramson VG, Sanders MS, Lush RM, Sorrentino C, Majumder S, Miele L. A Phase Ib Dose Escalation Trial of RO4929097 (a γ-secretase inhibitor) in Combination with Exemestane in Patients with ER + Metastatic Breast Cancer (MBC). Clin Breast Cancer. 2021 Oct 28:S1526-8209(21)00304-9. doi: 10.1016/j.clbc.2021.10.013. Online ahead of print.PMID: 34903452 Publication link.

 

Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)

Gnant M, Dueck AC, Frantal S, Martin M, Burstein HJ, Greil R, Fox P, Wolff AC, Chan A, Winer EP, Pfeiler G, Miller KD, Colleoni M, Suga JM, Rubovsky G, Bliss JM, Mayer IA, Singer CF, Nowecki Z, Hahn O, Thomson J, Wolmark N, Amillano K, Rugo HS, Steger GG, Hernando Fernández de Aránguiz B, Haddad TC, Perelló A, Bellet M, Fohler H, Metzger Filho O, Jallitsch-Halper A, Solomon K, Schurmans C, Theall KP, Lu DR, Tenner K, Fesl C, DeMichele A, Mayer EL; PALLAS groups and investigators. Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). J Clin Oncol. 2021 Dec 7:JCO2102554. doi: 10.1200/JCO.21.02554. Online ahead of print.PMID: 34874182 Publication link.

Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131

Mayer IA, Zhao F, Arteaga CL, Symmans WF, Park BH, Burnette BL, Tevaarwerk AJ, Garcia SF, Smith KL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Tawfik B, Flaum LE, Mayer EL, Sikov WM, Rodler ET, Wagner LI, DeMichele AM, Sparano JA, Wolff AC, Miller KD. Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131. J Clin Oncol. 2021 Jun 6:JCO2100976. doi: 10.1200/JCO.21.00976. Online ahead of print.PMID: 34092112 Publication link.

Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab

Metzger Filho O, Viale G, Stein S, Trippa L, Yardley DA, Mayer IA, Abramson VG, Arteaga CL, Spring LM, Waks AG, Wrabel E, DeMeo MK, Bardia A, Dell'Orto P, Russo L, King TA, Polyak K, Michor F, Winer EP, Krop IE. Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab. Cancer Discov. 2021 May 3:candisc.1557.2020. doi: 10.1158/2159-8290.CD-20-1557. Online ahead of print.PMID: 33941592 Publication link.

Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1

Ciruelos EM, Rugo HS, Mayer IA, Levy C, Forget F, Delgado Mingorance JI, Safra T, Masuda N, Park YH, Juric D, Conte P, Campone M, Loibl S, Iwata H, Zhou X, Park J, Ridolfi A, Lorenzo I, André F. Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1. J Clin Oncol. 2021 Mar 29:JCO2001139. doi: 10.1200/JCO.20.01139. Online ahead of print.PMID: 33780274 Publication link.

Clinical and biomarker results from phase I/II study of PI3K inhibitor alpelisib plus nab-paclitaxel in HER2-negative metastatic breast cancer

Sharma P, Abramson VG, O'Dea AP, Nye L, Mayer IA, Pathak HB, Hoffmann M, Stecklein SR, Elia M, Lewis S, Scott J, De Jong JA, Wang YY, Yoder R, Schwensen K, Finke K, Heldstab J, LaFaver S, Williamson S, Phadnis MA, Reed GA, Kimler BF, Khan QJ, Godwin AK. Clinical and biomarker results from phase I/II study of PI3K inhibitor alpelisib plus nab-paclitaxel in HER2-negative metastatic breast cancer. Clin Cancer Res. 2021 Feb 18:clincanres.4879.2020. doi: 10.1158/1078-0432.CCR-20-4879. Online ahead of print.PMID: 33602685 Publication link.

Racial/Ethnic Disparities in All-Cause Mortality Among Patients Diagnosed with Triple-Negative Breast Cancer

Wang F, Zheng W, Bailey CE, Mayer IA, Pietenpol JA, Shu XO. Racial/Ethnic Disparities in All-Cause Mortality Among Patients Diagnosed with Triple-Negative Breast Cancer. Cancer Res. 2020 Dec 3:canres.3094.2020. doi: 10.1158/0008-5472.CAN-20-3094. Online ahead of print.PMID: 33272926 Publication link.

Alpelisib Plus Fulvestrant for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: Final Overall Survival Results From SOLAR-1

André F, Ciruelos EM, Juric D, Loibl S, Campone M, Mayer IA, Rubovszky G, Yamashita T, Kaufman B, Lu YS, Inoue K, Pápai Z, Takahashi M, Ghaznawi F, Mills D, Kaper M, Miller M, Conte PF, Iwata H, Rugo HS. Alpelisib Plus Fulvestrant for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: Final Overall Survival Results From SOLAR-1. Ann Oncol. 2020 Nov 24:S0923-7534(20)43166-7. doi: 10.1016/j.annonc.2020.11.011. Online ahead of print.PMID: 33246021. Publication link.

Race, ethnicity and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer in the randomized TAILORx trial

Albain KS, Gray RJ, Makower DF, Faghih A, Hayes DF, Geyer CE, Dees EC, Goetz MP, Olson JA, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Wood WC, Keane MM, Gomez HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW, Sparano JA. Race, ethnicity and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer in the randomized TAILORx trial. J Natl Cancer Inst. 2020 Sep 28:djaa148. doi: 10.1093/jnci/djaa148. Online ahead of print.PMID: 32986828. Publication link.

Sacituzumab Govitecan in Previously Treated Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Final Results from a Phase 1/2, Single-Arm, Basket Trial

Kalinsky K, Diamond JR, Vahdat LT, Tolaney SM, Juric D, O'Shaughnessy J, Moroose RL, Mayer IA, Abramson VG, Goldenberg DM, Sharkey RM, Maliakal P, Hong Q, Goswami T, Wegener WA, Bardia A. Sacituzumab Govitecan in Previously Treated Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Final Results from a Phase 1/2, Single-Arm, Basket Trial. Ann Oncol. 2020 Sep 15:S0923-7534(20)42445-7. doi: 10.1016/j.annonc.2020.09.004. Online ahead of print.PMID: 32946924. Publication link.

Veeva ID: Z4-40714
Date of preparation: December 2021